Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to $1.3 million.

  • Ultragenyx Pharmaceutical's Capital Expenditures fell 2096.47% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 million, marking a year-over-year decrease of 3225.08%. This contributed to the annual value of $7.5 million for FY2024, which is 8307.77% down from last year.
  • Per Ultragenyx Pharmaceutical's latest filing, its Capital Expenditures stood at $1.3 million for Q3 2025, which was down 2096.47% from $2.2 million recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's 5-year Capital Expenditures high stood at $32.2 million for Q1 2022, and its period low was $654000.0 during Q4 2024.
  • In the last 5 years, Ultragenyx Pharmaceutical's Capital Expenditures had a median value of $13.9 million in 2023 and averaged $12.9 million.
  • As far as peak fluctuations go, Ultragenyx Pharmaceutical's Capital Expenditures soared by 44391.53% in 2021, and later tumbled by 9406.75% in 2023.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Capital Expenditures (Quarter) stood at $16.0 million in 2021, then surged by 68.06% to $27.0 million in 2022, then tumbled by 94.07% to $1.6 million in 2023, then tumbled by 59.13% to $654000.0 in 2024, then soared by 95.41% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $2.2 million for Q2 2025, and $1.6 million during Q1 2025.